MedStar Authors catalog › Details for: Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study.
Normal view MARC view ISBD view

Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study.

by Asch, Federico M.
Citation: Journal of Thoracic & Cardiovascular Surgery. 148(4):1681-7, 2014 Oct..Journal: The Journal of thoracic and cardiovascular surgery.ISSN: 0022-5223.Full author list: Englberger L; Carrel TP; Doss M; Sadowski J; Bartus K; Eckstein FF; Asch FM; Martens S.UI/PMID: 24787699.Subject(s): Aged | *Aortic Valve/su [Surgery] | *Aortic Valve Stenosis/su [Surgery] | *Bioprosthesis | Echocardiography | Female | Follow-Up Studies | *Heart Valve Prosthesis | *Heart Valve Prosthesis Implantation/mt [Methods] | Hemodynamics | Humans | Longitudinal Studies | Male | Postoperative Complications/ep [Epidemiology] | Prospective Studies | Prosthesis Design | Sternotomy | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Online resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: J Thorac Cardiovasc Surg. 148(4):1681-7, 2014 Oct.Local Holdings: Available online from MWHC library: 1994 - present, Available in print through MWHC library: 1999 - 2006.Abstract: OBJECTIVE: Sutureless valves are designed to facilitate surgical implantation, including less-invasive techniques in aortic valve replacement, by maintaining surgical precision of implantation compared with transcatheter techniques. Long-term clinical experience with sutureless valves is lacking. We report the 5-year follow-up results of an international, prospective, multicenter study evaluating the clinical performance and safety of the 3f Enable valve (Medtronic Inc, Minneapolis, Minn).Abstract: METHODS: Between March 2007 and December 2009, 141 patients (54 male; mean age, 76.1+/-5.7 years) undergoing aortic valve replacement with the 3f Enable valve were enrolled in 10 European sites. The mean follow-up was 2.76 years (range, 2 days to 5.1 years; total, 388.7 patient-years). Echocardiographic valvular hemodynamic and morphologic analyses were performed by an independent core laboratory.Abstract: RESULTS: The mean systolic gradient was 10.4+/-4.4 mm Hg at discharge and 7.7+/-4.1 mm Hg at 5 years. The mean effective orifice area was 1.7+/-0.5 cm2 at discharge and 1.6+/-0.2 cm2 at 5 years. Freedom from all-cause and valve-related mortality was 87.6%+/-2.9% and 96.8%+/-1.6% at 1 year (113 patients at risk) and 77.0%+/-7.5% and 93.8%+/-4.8% at 5 years (24 patients at risk), respectively. Six patients underwent reoperation (4 because of major paravalvular leakage and 2 because of endocarditis). Freedom from reoperation was 95.4%+/-1.9% at 1 year and 95.4%+/-6.1% at 5 years. No structural valve deterioration occurred during the follow-up period.Abstract: CONCLUSIONS: The sutureless 3f Enable valve represents a safe and effective treatment for aortic valve stenosis, providing an excellent hemodynamic profile. This study represents the longest follow-up study for a sutureless bioprosthesis. Sutureless valves may become an option for all patients with indicated biological aortic valve replacement.Copyright � 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Powered by Koha